Inhibition of mutated, activated BRAF in metastatic melanoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Indoles
  • Melanoma
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)

publication date

  • August 26, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3724529

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1002011

PubMed ID

  • 20818844

Additional Document Info

start page

  • 809

end page

  • 19

volume

  • 363

number

  • 9